A Case of Good Efficacy of Tolvaptan in a Patient with Markedly Enlarged Polycystic Kidney
Article Sidebar
Main Article Content
Abstract
A 61-year-old patient with autosomal dominant polycystic kidney disease (Irazabal class 1E) in whom renal function had decreased and kidney size had increased over the past 3 years (change in serum creatinine, 1.3 mg/dL to 1.5 mg/dL; change in total kidney volume, 5632 cm3 to 7301 cm3) was treated with tolvaptan 60 mg/day. After 8 years of tolvaptan treatment, serum creatinine remained at 1.51 mg/dL, and total kidney volume was at 6812 cm3. Adequate salt intake and good weight control may have resulted in good outcomes, even in patients with treatment-resistant giant cystic kidney disease.
Article Details
Copyright (c) 2024 Mizuta M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, et al. CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122-2130. Available from: https://doi.org/10.1056/nejmoa054341
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418. Available from: https://doi.org/10.1056/nejmoa1205511
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. CRISP Investigators. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-172. Available from: https://doi.org/10.1681/asn.2013101138
Ohshima S. Volume analyzer SYNAPSE VINCENT for liver analysis. J Hepatobiliary Pancreat Sci. 2014;21(4):235-238. Available from: https://doi.org/10.1002/jhbp.81
Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial. Kidney Int Rep. 2016;1(4):213-220. Available from: https://doi.org/10.1016/j.ekir.2016.08.001
Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, et al. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2021;25(5):467-478. Available from: https://doi.org/10.1007%2Fs10157-020-02009-0
Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, et al. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease. J Nephrol. 2018;31(6):961-966. Available from: https://doi.org/10.1007/s40620-018-0545-8
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2018;33(3):477-489. Available from: https://doi.org/10.1093/ndt/gfx043
Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13(8):1153-1161. Available from: https://doi.org/10.2215%2FCJN.01520218
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470. Available from: https://doi.org/10.1681/asn.2018060590